Legal & General Group Plc increased its holdings in shares of Immunocore Holdings plc (NASDAQ:IMCR - Free Report) by 17.3% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 136,875 shares of the company's stock after purchasing an additional 20,163 shares during the quarter. Legal & General Group Plc owned 0.27% of Immunocore worth $4,038,000 as of its most recent filing with the SEC.
A number of other large investors have also bought and sold shares of the business. China Universal Asset Management Co. Ltd. grew its stake in shares of Immunocore by 12.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,393 shares of the company's stock worth $248,000 after acquiring an additional 960 shares in the last quarter. NEOS Investment Management LLC grew its stake in shares of Immunocore by 10.9% during the 4th quarter. NEOS Investment Management LLC now owns 11,194 shares of the company's stock worth $330,000 after acquiring an additional 1,102 shares in the last quarter. Assetmark Inc. grew its stake in shares of Immunocore by 5.3% during the 4th quarter. Assetmark Inc. now owns 32,171 shares of the company's stock worth $949,000 after acquiring an additional 1,616 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Immunocore by 1.2% during the 4th quarter. Geode Capital Management LLC now owns 35,492 shares of the company's stock worth $1,047,000 after acquiring an additional 420 shares in the last quarter. Finally, Crossmark Global Holdings Inc. grew its stake in shares of Immunocore by 36.7% during the 4th quarter. Crossmark Global Holdings Inc. now owns 38,020 shares of the company's stock worth $1,121,000 after acquiring an additional 10,217 shares in the last quarter. 84.50% of the stock is owned by institutional investors.
Immunocore Stock Performance
Immunocore stock traded up $0.45 during mid-day trading on Monday, hitting $30.61. 169,696 shares of the company's stock traded hands, compared to its average volume of 437,022. The firm has a 50 day simple moving average of $28.79 and a two-hundred day simple moving average of $30.34. Immunocore Holdings plc has a fifty-two week low of $23.15 and a fifty-two week high of $62.74. The stock has a market cap of $1.53 billion, a price-to-earnings ratio of -32.22 and a beta of 0.75. The company has a debt-to-equity ratio of 1.03, a current ratio of 3.78 and a quick ratio of 3.76.
Analyst Ratings Changes
Several equities analysts have recently weighed in on IMCR shares. Needham & Company LLC reaffirmed a "buy" rating and set a $71.00 price target on shares of Immunocore in a research note on Thursday, April 10th. Mizuho decreased their price target on shares of Immunocore from $38.00 to $33.00 and set a "neutral" rating for the company in a research note on Monday, April 7th. HC Wainwright reissued a "buy" rating and issued a $100.00 price objective on shares of Immunocore in a report on Wednesday, March 12th. JPMorgan Chase & Co. cut their price objective on Immunocore from $54.00 to $50.00 and set an "overweight" rating for the company in a report on Monday, April 14th. Finally, Morgan Stanley reissued an "equal weight" rating and issued a $35.00 price objective on shares of Immunocore in a report on Friday, March 7th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and eight have issued a buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $60.90.
View Our Latest Stock Analysis on Immunocore
Insider Buying and Selling at Immunocore
In other Immunocore news, Director Bros. Advisors Lp Baker purchased 807,338 shares of the firm's stock in a transaction that occurred on Monday, March 17th. The shares were acquired at an average cost of $29.72 per share, for a total transaction of $23,994,085.36. Following the completion of the purchase, the director now owns 2,144,060 shares of the company's stock, valued at approximately $63,721,463.20. The trade was a 60.40 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 10.40% of the company's stock.
Immunocore Profile
(
Free Report)
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.
Featured Stories
Before you consider Immunocore, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunocore wasn't on the list.
While Immunocore currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
